Baxter to sell its BioPharma business for $4.25 billion to Advent International, Warburg Pincus as part of ‘transformation journey’

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 14 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 97%

Nederland Nieuws Nieuws

Nederland Laatste Nieuws,Nederland Headlines

Shares of Baxter International Inc. rose 1.2% in premarket trading Monday, after the health care products company announced an agreement to divest its...

Shares of Baxter International Inc. BAX rose 1.2% in premarket trading Monday, after the health care products company announced an agreement to divest its BioPharma Solutions business to private-equity investor Advent International and Warburg Pincus. Under terms of the agreement, Baxter will receive $4.25 billion in cash, which the company plans to use to pay down debt.

Under terms of the agreement, Baxter will receive $4.25 billion in cash, which the company plans to use to pay down debt. The company expects the deal, which is expected to close in the second half of 2023, to reduce fourth-quarter earnings by about 10 cents a share.

Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder:

 /  🏆 3. in NL
 

Bedankt voor uw reactie. Uw reactie wordt na beoordeling gepubliceerd.

Nederland Laatste Nieuws, Nederland Headlines